Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;104(4):2483-2493.
doi: 10.1007/s00277-025-06350-w. Epub 2025 Apr 15.

Allogeneic transplantation for CML blast phase: Learnings over last decade from a single centre in North India

Pritish Chandra Patra  1 , Sujay Rainchwar  2 , Reema Singh  3 , Niharika Bhatia  3 , Sakshi Bhatnagar  3 , Roy J Palatty  3 , Nakul Tikare  3 , Tribikram Panda  3 , Vipul Sharad Sheth  3 , Narendra Agrawal  3 , Rohan Halder  4 , Dinesh Bhurani  3
Affiliations

Allogeneic transplantation for CML blast phase: Learnings over last decade from a single centre in North India

Pritish Chandra Patra et al. Ann Hematol. 2025 Apr.

Abstract

Chronic myeloid leukemia in the blast phase (BP-CML) remains challenging despite advancements in tyrosine kinase inhibitors (TKIs). This study retrospectively assessed BP-CML patients who underwent allogeneic stem cell transplantation (allo-SCT) from June 2009 to December 2022. Thirty-three patients were included and the median age was 41 years, with a predominantly male cohort. Myeloablative conditioning and peripheral blood stem cells were used in the majority of the patients. The estimated 2-year overall survival (OS) was 48.3% of the cohort. Relapse occurred in 48.5% of patients, typically within 3 months post-transplant. Post-transplant TKI maintenance showed a significant association with improved OS (p-value = 0.001). The study highlights the need for early intervention and optimized post-transplant maintenance to improve outcomes.

Keywords: Allo-SCT; Blast phase; CML; India; Real-world; TKI.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval statement: The study has been approved by the Institutional Review Board of our Centre. Patient consent statement: Patient Permission to publish the data has been taken from the patient. Competing interests: The authors declare no competing interests. Declaration of generative AI and AI-assisted technologies in the writing process:: During the preparation of this work the author(s) used ChatGPT in order to improve Grammatical errors of the manuscript. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

Figures

Fig. 1
Fig. 1
Kaplan Meier Curve depicting the overall survival (OS) of the cohort
Fig. 2
Fig. 2
a Kaplan Meier Curve depicting the overall survival (OS) of pre- 2016 and post- 2016 phase. b Kaplan Meier Curve depicting the progression-free survival (PFS) of pre- 2016 and post- 2016 phase
Fig. 3
Fig. 3
a Cumulative Incidence of Relapse (CIR) of the entire cohort. b Cumulative Incidence of Relapse (CIR) of the pre- 2016 and post- 2016 group
See this image and copyright information in PMC

References

    1. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J F, ... & Hochhaus A. (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia, 36(7), 1703–1719 - PMC - PubMed
    1. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408–2417 - PubMed
    1. Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34:2851–2857 - PubMed
    1. Hehlmann R (2020) Chronic myeloid leukemia in 2020. Hemasphere 4:e468 - PMC - PubMed
    1. Hochhaus A, Baccarani M, Silver RT et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(04):966–984 - PMC - PubMed

MeSH terms

Substances